BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, January 28, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2003

View Archived Issues

Phytopharm reports quarterly development highlights

Read More

First-quarter progress at Medivir

Read More

Ciclosporin analogues for autoimmune diseases designed at Enanta

Read More

Memory Pharmaceuticals presents new PDE4 inhibitors for use in cognition disorders

Read More

Novel glucose-lowering 11CBy antagonists identified at GSK

Read More

Antitumor dolastatin derivative isolated and tested by Spanish researchers

Read More

Allergan patent covers new analgesic agents, their preparation and use

Read More

Bayer researchers present new adenosine uptake inhibitors

Read More

Scientists at Janssen identify new delta opioid receptor agonists

Read More

Checkpoint kinase inhibitors and their use as adjuvants in DNA-damaging cancer therapy

Read More

New antiobesity MCHR1 antagonists in GSK pipeline

Read More

Dietary omega n-3 LCPUFAs reduce the risk for AMD

Read More

Timolol-LA reported as effective as timolol maleate in reducing ocular hypertension

Read More

Regulatory approval sought for Fendrix

Read More

Theralux granted orphan drug status for CML

Read More

QLT discontinues phase III trials of tariquidar in NSCLC

Read More

Rifaximin does not promote antibacterial resistance in Salix study

Read More

At-home phase IIb study begins for ED treatment PT-141

Read More

Onconase to be tested in federal SARS program

Read More

Trillium Therapeutics approved as new name for Transplantation Technologies

Read More

IND filed for phase II trials of SPI-0211 in postoperative ileus

Read More

Phase IIa trial evaluates VR-004 delivered via lungs for ED

Read More

Dacogen granted fast track status for MDS

Read More

FDA advisory committee hands down favorable decision on atazanavir

Read More

Completely new approach to cancer treatment given the go-ahead by the FDA for multiple myeloma

Read More

Botanical product for hypertriglyceridemia unveiled at recent meeting

Read More

CellGate ciclosporin prodrug shows favorable PK and safety profile following topical administration

Read More

BM-573 prevents coronary artery thrombosis and myocardial infarction

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 28, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing